mutations was employed. In other terms, while B-CLL with a low mutation 'load' had longer survivals if evidence of antigendriven selection can be documented, survivals of B-CLLs bearing heavily mutated IgV H gene products (X4% mutations) seem to be independent of any evidence of affinity maturation.
In addition to its obvious clinical impact, this observation provides a putative explanation of the apparent discrepancies between the study of Lane et al 2 and that of our group. 4 Since in the B-CLL series reported by Lane et al 2 only a cutoff set at 5% IgV H mutations was able to segregate patients into two groups with different survivals, it is not surprising that the affinity maturation status failed to have a prognostic impact in their cohort of patients.
The different results obtained by Lane et al 2 might be explained by considering some peculiar features of their B-CLL cohort of patients, as compared to that reported in our study: 4 At least three subtypes of human acute megakaryoblastic leukemia (AMKL) exist: (1) pediatric de novo AMKL, which is associated with a characteristic t(1;22)(p13;q13) in approximately two-thirds of AMKL in infants, (2) pediatric AMKL in the setting of Down Syndrome, and (3) adult AMKL. 1 We and others recently reported the involvement of two novel genes, RBM15 (alternatively known as OTT) and MKL1 (alternative name, MAL), in the t(1;22) associated with de novo infant and early childhood AMKL. 2, 3 In addition, mutations of the GATA-1 transcription factor gene are associated with the transient leukemias (TLs) and AMKLs associated with Down Syndrome, and are hypothesized to contribute to their development. [4] [5] [6] As the t(1;22) is observed exclusively in AMKL, we hypothesized that the RBM15 and MKL1 genes might play key roles in the pathogenesis of other AMKLs that lack the t(1;22). To Patient A3 is identical to patient T1. NA: not available, ND: not determined, CML: chronic myelogenous leukemia, ET: essential thrombocythemia. All cell lines, except for SET-2 and KOPMK42, were purchased from the ATCC or DSMZ. a Megakaryocytic transformation. b Leukemic transformation. c Expression of intact GATA-1 has been reported. 4 address this possibility, we screened cell lines established from both pediatric and adult AMKLs, as well as clinical samples from infants and children with Down Syndrome-associated TL and AMKL, for mutations that would affect the normal functions of RBM15 or MKL1. Seven cell lines, and 11 clinical samples, were included in this study (Table 1) . For the clinical samples, the diagnosis of TL or AMKL was based on the presence of characteristic morphologic features and the immunophenotypic demonstration of megakaryoblastic markers. The GATA-1 mutational status of these TL and AMKL cases was recently reported by Hitzler et al.
5 (see Table 1 ). Genomic DNA was amplified using PCR primers (see Supplementary Information for complete methods and primer sequences) designed to amplify all of the coding exons of RBM15 and MKL1, including the splice acceptor and donor sequences associated with each exon, as well as both 5 0 and 3 0 UTR sequences, and the amplified PCR products were sequenced.
Two SNPs previously catalogued in the NCBI SNP database were identified in RBM15 exon 1 (Table 1) . Likewise, three previously identified SNPs were found in MKL1 exons 12 and 15. Two additional nucleotide substitutions were found in RBM15, one of which occurred in codon 536Gln and was silent (ie, caused no amino-acid change) and another that occurred in the 3 0 UTR and was also identified in human placental DNA; both of these substitutions likely represent newly identified SNPs. Although SNPs can potentially have influences upon the expression of genes and their encoded proteins, 7 examination by RT-PCR did not show significant differences in transcription levels of either RBM15 or MKL1 between cell lines with and without SNPs (data not shown). No nucleotide alterations predicted to result in alterations in gene promoter functions, codon alterations, abnormalities of exon splicing, or mRNA transcript stability (eg, as can occur due to mutations in certain 3 0 UTR sequences) 8 were identified in either gene. Thus, despite the involvement of RBM15 and MKL1 in the AMKL-specific t(1;22)-associated RBM15-MKL1 fusion, our data suggest it unlikely that mutations affecting the function of either of these proteins may account as a major cause of megakaryoblastic transformation in cases that lack the t(1;22) -especially in TL and AMKL cases associated with Down Syndrome, from which the clinical samples studied herein were derived. GATA1 mutation occurs in the majority of Down Syndrome TLs and AMKLs, but the genes cooperating with mutated GATA1 during leukemogenesis are not known; our data suggest that neither RBM15 nor MKL1 are likely candidates for GATA1-cooperating genes.
